Peptide Cancer Vaccine Market
完整報告名稱與涵蓋範圍
Peptide Cancer Vaccine Market Size, Share & Trends Analysis By Type (Multivalent Peptide Vaccine, Personalized Peptide Vaccine, Peptide Cocktail Type, Hybrid Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine), By Application (Breast Cancer, Prostate Cancer, Lung Cancer, Melanoma), by Region, And by Segment Forecasts, 2025-2034.
報告摘要
In 2024, the Peptide Cancer Vaccine Market worldwide was assessed at USD 1.6 Bn. Analysts project it will increase to USD 13.9 Bn by 2034, at a CAGR of 24.5% spanning 2025 to 2034.
The Peptide Cancer Vaccine sector involves dynamics.
The market's upward path is underpinned by rising healthcare spending, technological evolution, and the rising focus on personalized and precision-based approaches in healthcare.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold notable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and rising investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Peptide Cancer Vaccine Market Snapshot
Chapter 4. Global Peptide Cancer Vaccine Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Peptide Cancer Vaccine Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Peptide Cancer Vaccine Market Industry Trends
Chapter 5. Peptide Cancer Vaccine Market Segmentation 1: By Type, Estimates & Trend Analysis
5.1. Market Share by Type, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:
5.2.1. Multivalent Peptide Vaccine
5.2.2. Peptide Cocktail Type
5.2.3. Personalized Peptide Vaccine
5.2.4. Peptide-Pulsed Dendritic Cancer Vaccine
5.2.5. Hybrid Peptide Vaccine
Chapter 6. Peptide Cancer Vaccine Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the
following Application:
6.2.1. Breast Cancer
6.2.2. Lung Cancer
6.2.3. Melanoma
6.2.4. Prostate Cancer
Chapter 7. Peptide Cancer Vaccine Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. Global Peptide Cancer Vaccine Market, Regional Snapshot 2024 & 2034
7.2. North America
7.2.1. North America Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
7.2.1.1. US
7.2.1.2. Canada
7.2.2. North America Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
7.2.3. North America Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
7.3. Europe
7.3.1. Europe Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
7.3.1.1. Germany
7.3.1.2. U.K.
7.3.1.3. France
7.3.1.4. Italy
7.3.1.5. Spain
7.3.1.6. Rest of Europe
7.3.2. Europe Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
7.3.3. Europe Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
7.4. Asia Pacific
7.4.1. Asia Pacific Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
7.4.1.1. India
7.4.1.2. China
7.4.1.3. Japan
7.4.1.4. Australia
7.4.1.5. South Korea
7.4.1.6. Hong Kong
7.4.1.7. Southeast Asia
7.4.1.8. Rest of Asia Pacific
7.4.2. Asia Pacific Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
7.4.3. Asia Pacific Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
7.5. Latin America
7.5.1. Latin America Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Rest of Latin America
7.5.2. Latin America Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
7.5.3. Latin America Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
7.6. Middle East & Africa
7.6.1. Middle East & Africa Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
7.6.1.1. GCC Countries
7.6.1.2. Israel
7.6.1.3. South Africa
7.6.1.4. Rest of Middle East and Africa
7.6.2. Middle East & Africa Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
7.6.3. Middle East & Africa Peptide Cancer Vaccine Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Imugene
8.2.1.1. Business Overview
8.2.1.2. Key Type/Service
8.2.1.3. Financial Performance
8.2.1.4. Geographical Presence
8.2.1.5. Recent Developments with Business Strategy
8.2.2. Generex Biotechnology
8.2.3. BrightPath Biotherapeutics
8.2.4. Sellas
8.2.5. TapImmune
8.2.6. OncoTherapy Science
8.2.7. VAXON Biotech
8.2.8. Boston Biomedical
8.2.9. Ultimovacs
8.2.10. Immatics
8.2.11. ISA Pharmaceuticals
8.2.12. Others
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們